Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial
Lassen et al 2026
Analysis of microbiology assay sensitivity and intradiscal antibiotic exposure in patients with chronic low back pain with Modic changes
Gilligan et al 2026
PP353 Intradiscal Linezolid for Modic Type 1 cLBP: A Double‑Blinded, Sham‑Controlled Phase 1b Study
McHale et al 2026
Chronic low back pain, bacterial infection and treatment with antibiotics
Gilligan et al 2021
Intradiscal pharmacokinetics of oral antibiotics to treat Chronic Lower Back Pain
Czaplewski et al 2023
Modic changes as seen on MRI are associated with nonspecific chronic lower back pain and disability
Czaplewski et al 2023
Preclinical development and characterisation of PP353, a formulation of linezolid for intradiscal administration
Hagger et al 2024
Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first-in-human, Phase 1b, open-label, single-dose study
Tripathi et al 2024
